Is there a role for maintenance therapy in acute myeloid leukaemia?

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 4, 2009, Pages 517-521

  Baer, Maria R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

acute myeloid leukaemia; demethylating agents; FLT3; histamine; immunotherapy; interleukin 2; lestaurtinib; maintenance; midostaurin; tipifarnib; vaccines

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; HISTAMINE; IMATINIB; INTERLEUKIN 2; LESTAURTINIB; MERCAPTOPURINE; METHOTREXATE; MIDOSTAURIN; PEPTIDE VACCINE; PLACEBO; RETINOIC ACID; TIPIFARNIB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE;

EID: 71849109098     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.09.001     Document Type: Review

References (20)

1. Pui C.H., and Evans W.E. Treatment of acute lymphoblastic leukemia. The New England journal of medicine 354 (2006) 166-178
2. Jabbour E.J., Faderl S., and Kantarjian H.M. Adult acute lymphoblastic leukemia. Mayo Clinic proceedings 80 (2005) 1517-1527
3. Sanz M.A., Grimwade D., Tallman M.S., et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113 (2009) 1875-1891
4. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. The lancet oncology 10 (2009) 223-232
5. Appelbaum F.R., Gundacker H., Head D.R., Slovak M.L., Willman C.L., Godwin J.E., Anderson J.E., and Petersdorf S.H. Age and acute myeloid leukemia. Blood 107 (2006) 3481-3485
6. Raza A., Maheshwari Y., and Preisler H.D. Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia. Blood 69 (1987) 1647-1653
7. Preisler H., Davis R.B., Kirshner J., et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood 69 (1987) 1441-1449
8. Sauter C., Berchtold W., Fopp M., et al. Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet 1 (1984) 379-382
9. Lowenberg B., Suciu S., Archimbaud E., et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European organization for the research and treatment of cancer and the Dutch-Belgian hemato-oncology cooperative hovon group. Journal of Clinical Oncology 16 (1998) 872-881
10. Miyawaki S., Sakamaki H., Ohtake S., et al. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult leukemia study group AML 97 study. Cancer 104 (2005) 2726-2734
11. Baer M.R., George S.L., Caligiuri M.A., et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. Journal of Clinical Oncology 26 (2008) 4934-4939
12. Kolitz J.E., Hars V., DeAngelo D.J., et al. Phase III trial of immunotherapy with recombinant interleukin-2 (rIL-2) versus observation in patients < 60 years with acute myeloid leukemia (AML) in first remission (CR1): preliminary results from Cancer and Leukemia Group B (CALGB) 19808. Blood 110 (2007) 53a abstr 157
13. Brune M., Castaigne S., Catalano J., et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 108 (2006) 88-96
14. Greiner J., Döhner H., and Schmitt M. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 91 (2006) 1653-1661
15. Houtenbos I., Westers T.M., Ossenkoppele G.J., and van de Loosdrecht A.A. Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia. Haematologica 91 (2006) 348-355
16. National Cancer Institute. Phase II study of maintenance therapy with decitabine after standard induction and cytogenetic risk-adapted intensification in patients with previously untreated acute myeloid leukemia. Clinical Trials (PDQ) 5/13/2009.
17. Thomas D.A., Faderl S., Cortes J., et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103 (2004) 4396-4407
18. Karp J.E., Smith B.D., Gojo I., et al. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clinical cancer research 14 (2008) 3077-3082
19. Stone R.M., DeAngelo D.J., Klimek V., et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105 (2005) 54-60
20. Piloto O., Wright M., Brown P., et al. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood 109 (2007) 1643-1652